Metformin Sandoz

Metformin Sandoz is a generic version of the widely prescribed medication metformin, used primarily to manage blood glucose levels in patients with type 2 diabetes. The brand Sandoz has a historical lineage dating back to 1886 in Switzerland, where it focused on chemical production before evolving into a global pharmaceutical powerhouse.

Starting in 2023, Sandoz became a fully independent, publicly-traded company following its successful spin-off from the Swiss multinational Novartis. This transition allowed Sandoz to refocus exclusively on its mission as a global leader in generic and biosimilar medicines. While the brand originated in Switzerland, its manufacturing network is global, utilizing facilities across Europe, Asia, and the Americas to ensure supply for various international markets including Australia.